All In Biotech

Free tool

FAERS Monitor: Winrevair

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761363 or its brand name (Winrevair, Sotatercept-Csrk). Reports on generic versions are filed under their own applications.

Reports

6,188

Serious

3,495

56% of reports

Hospitalization

2,598

Death reported

286

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache826
  • dyspnoea698
  • diarrhoea639
  • fatigue548
  • epistaxis537
  • nausea507
  • dizziness504
  • haemoglobin increased315
  • cough275
  • dyspnoea exertional274
  • vomiting256
  • product dose omission issue253
  • hypotension236
  • weight decreased234
  • pain in extremity233

Reports by year received

View as table
YearReports
20212
20224
202340
2024782
20252,268
20263,092

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemoglobin increasedSignal315252.0225.473,114
dyspnoea exertionalSignal27424.922.26,227
epistaxisSignal53724.622.712,075
headacheSignal8264.54.22,297
dyspnoeaSignal6984.23.91,740
hypotensionSignal2364.03.5533
dizzinessSignal5043.43.2889
diarrhoeaSignal6393.43.11,093
coughSignal2753.33.0453
product dose omission issueSignal2532.92.6323
weight decreasedSignal2342.92.5283
pain in extremitySignal2332.72.4249
fatigueSignal5482.42.2460
nauseaSignal5072.22.0334
vomiting2561.91.6102

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.